A staggering 80% of solid organ tumors produce antigens recognized by the immune system, yet they often evade effective treatment. While oncology has seen significant advancements in blood cancers, solid tumors like lung, breast, and pancreatic cancers remain challenging. The conversation reveals that the immune response is hindered by insufficient T cells or their inhibition, raising critical questions about how to harness this potential for better outcomes.
